Latest News for 07/2020
08 Jun 2020
Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete. One of the most powerful and versatile tools to better understand biology and disease-relevant processes are well-characterized small chemical modulators of protein function. The newly formed public-private partnership “Enabling and Unlocking biology in the OPEN” (EUbOPEN) aims to develop high quality chemical tool compounds for 1,000 proteins (one third of the druggable proteins in the human body).
18 May 2020
Proteolysis-targeting chimera (PROTAC) compounds developed at the University of Dundee are being made available free of charge by the pharmaceutical company Boehringer Ingelheim through their scientific crowdsourcing platform opnMe.com. The opnMe portal provides free and open access to selected molecules for the scientific community aiming at accelerating research initiatives that can benefit patients with high unmet medical need.
07 Apr 2020
A University of Dundee spinout has announced a multi-million pound deal to develop first-in-class cancer therapeutics that harness the body’s natural processes to selectively and efficiently degrade and remove disease causing proteins.
27 Nov 2019
Researchers in the Ciulli group report a first study describing the idea of a macrocyclic PROTAC. The research was published in the prestigious chemistry journal Angewandte Chemie. PROTACs (for proteolysis-targeting chimeras) are double-headed molecules composed of a ligand for a target protein and a ligand for an E3 ubiquitin ligase, chemically joined by a flexible linker. The PROTAC simultaneously recruits the target protein and the E3 ligase into close proximity, and this leads to the target protein being destroyed inside the cell.
29 Oct 2019
School of Life Science’s Professor Alessio Ciulli was amongst a selected group of world’s leading expert scientists and key opinion leaders who spoke at the Galien Forum on October 24, 2019, at the Alexandria Center in New York City. Alessio’s panel, entitled ‘Drugging the Undruggable with Novel Approaches to Small Molecule Design’, was chaired by Pfizer’s Chief Scientific Officer and President, Worldwide Research, Development and Medical, Mikael Dolsten.
29 Aug 2019
Hannah Tovell a PhD student in Dario Alessi lab working in collaboration with Claire Crafter (AstraZeneca) and Alessio Ciulli and Andrea Testa in his lab have elaborated a compound that we have termed SGK3-PROTAC1 that induces selective degradation of SGK3 protein kinase. Hannah was able to show that SGK3-PROTAC1 suppressed proliferation of ZR-75-1 and CAMA-1 cancer cell lines treated with a PI3K inhibitor (GDC0941) more effectively than could be achieved by a conventional SGK isoform inhibitor (14H), underscoring the benefit of the PROTAC approach.
University of Dundee and Eisai enter partnership for cancer drug discovery using targeted protein...08 Jul 2019
The University of Dundee has announced a new partnership with Eisai, one of the world’s leading research-based pharmaceutical companies, aiming to create innovative new drugs for the cancer field. The collaboration combines the world-leading PROTACs expertise and technology of Professor Alessio Ciulli from the Division of Biological Chemistry and Drug Discovery in the School with Eisai’s discovery research and clinical development experiences in oncology.
11 Jun 2019
In an article published today in the prestigious journal Nature Chemical Biology, scientists at the University of Dundee and Boehringer Ingelheim have made an important first stride toward drugging undruggable cancer targets using an innovative approach to drug discovery.
10 Jun 2019
Researchers in the laboratory of Professor Alessio Ciulli have revealed atomic-resolution images of how an E3 ubiquitin ligase enzyme involved in immune and cell signalling latches on to its protein partners. This is important because these binding events are required for the protein to function properly inside the cell.
15 Apr 2019
Hannah Tovell an Alessi lab PhD student working closely with the Ciulli lab has published an improved HaloPROTAC method to induce post–translational knockdown of endogenous proteins. This approach makes use of CRISPR/Cas9 genome editing technology to introduce a Halo tag onto the N or C terminus of any desired target protein that can then be targeted for degradation by a HaloPROTAC probe (see Figure).